UNSPSC 51373000: Controlled substance analgesic benzomorphans

Controlled substance analgesic drugs made from morphine derivatives of the methanobenzazocine family that act as potent analgesics.

UNSPSC 51373000 Controlled substance analgesic benzomorphans, a Class code, encompasses the procurement of pharmaceutical products and related systems for overdose response and drug management by state and local health agencies, counties, and multistate cooperative purchasing alliances. State and local governments buy naloxone products, safe drug deactivation systems, and generic multi-source pharmaceuticals under this code through competitive bidding, requests for proposal, and cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP) serving multiple participating jurisdictions across state lines, including Oregon. The work involves product procurement with specific delivery, compliance, and insurance requirements; vendors must meet FDA standards, Drug Supply Chain Security Act compliance, and Good Manufacturing Practices certification.

Recent activity shows geographic spread across Florida, Texas, and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023, though the posting date of June 30, 2026 appears misaligned with the response deadline) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, requiring vendors to cover all shipping costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing state pharmacy benefit relationships outside traditional pharmacy benefit managers and wholesalers. MMCAP issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities, with awards effective July 1, 2026 and contract terms of two years with optional extensions. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence and demonstrate pricing flexibility through multiple formats, with pricing competitiveness weighted at 75 percent of evaluation.